Puma Biotechnology, Inc.
PBYI
$3.07
-$0.04-1.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 46.01M | 59.08M | 80.54M | 47.08M | 43.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.01M | 59.08M | 80.54M | 47.08M | 43.77M |
| Cost of Revenue | 10.56M | 13.92M | 29.10M | 10.66M | 10.73M |
| Gross Profit | 35.45M | 45.16M | 51.45M | 36.43M | 33.04M |
| SG&A Expenses | 17.60M | 16.62M | 16.82M | 24.97M | 21.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.02M | 45.71M | 58.46M | 49.26M | 46.07M |
| Operating Income | 3.98M | 13.37M | 22.08M | -2.18M | -2.30M |
| Income Before Tax | 3.27M | 12.24M | 20.61M | -4.15M | -4.60M |
| Income Tax Expenses | 293.00K | -7.07M | 291.00K | 378.00K | 220.00K |
| Earnings from Continuing Operations | 2.97M | 19.31M | 20.32M | -4.53M | -4.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.97M | 19.31M | 20.32M | -4.53M | -4.82M |
| EBIT | 3.98M | 13.37M | 22.08M | -2.18M | -2.30M |
| EBITDA | 6.78M | 16.21M | 24.96M | 729.00K | 598.00K |
| EPS Basic | 0.06 | 0.39 | 0.41 | -0.09 | -0.10 |
| Normalized Basic EPS | 0.04 | 0.16 | 0.26 | -0.05 | -0.06 |
| EPS Diluted | 0.06 | 0.39 | 0.41 | -0.09 | -0.10 |
| Normalized Diluted EPS | 0.04 | 0.15 | 0.26 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 49.60M | 49.10M | 49.01M | 48.29M | 48.19M |
| Average Diluted Shares Outstanding | 49.91M | 49.41M | 49.17M | 48.29M | 48.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |